Latest news
Stay in the know about our progress, and visit our Newsroom
Combining scientific excellence, financial capacity and dealmaking experience, we believe in the power of strong partnerships to pioneer for patients, together.
Lakefront Biotherapeutics pursues a creative approach to collaboration, enabling a broad range of transaction structures—from co-development to strategic alliances that enhance scale and reach. Our long-standing collaboration with Gilead Sciences, initiated in 2015 around filgotinib and expanded through a 10-year R&D agreement in 2019, illustrates how working jointly can unlock greater development and commercialization opportunities.
Building on this approach, the pending acquisition of Ouro Medicines further extends our collaborative ecosystem and reinforces our ability to pursue diverse innovation pathways alongside others. Together, these models broaden the range of opportunities we can access and accelerate the delivery of impactful therapies.
If you believe your assets fit Lakefront Biotherapeutics’ strategy or like to learn more about our in-licensing or partnering efforts, please contact our Business Development team.
Please note that any business development proposals that are submitted via email or via our website will be considered non-confidential. No information exchange may be deemed confidential without a signed confidentiality or disclosure agreement from Lakefront Biotherapeutics.
Stay in the know about our progress, and visit our Newsroom
Looking for information about our company, our stock and our financials?